EE411 Cost-per-Responder Analysis of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.677
https://www.valueinhealthjournal.com/article/S1098-3015(23)03807-X/fulltext
Section Title :
Section Order :
10165
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03807-X&doi=10.1016/j.jval.2023.09.677